Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sarcosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sarcosine SCHEMBL16162573 | 0.94 | — | — | |
| Sarcosine SCHEMBL30313616 | 0.94 | CTH (0.42) | — | |
| Sarcosine SCHEMBL28606783 | 0.94 | CTH (0.42) | — | |
| Sarcosine SCHEMBL177631 | 0.94 | — | — | |
| Sarcosine SCHEMBL156329 | 0.91 | LDHA (0.44) | — | |
| Sarcosine SCHEMBL28259932 | 0.91 | — | — | |
| Sarcosine SCHEMBL31427574 | 0.91 | — | — | |
| Sarcosine SCHEMBL26641423 | 0.91 | LDHA (0.44) | — | |
| Sarcosine SCHEMBL149 | 0.91 | — | — | |
| Sarcosine SCHEMBL30041097 | 0.88 | CTH (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269499-A1 | CRYSTALLINE FORMS AND PROCESS FOR PREPARING SPIRO-HYDANTOIN COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-30 | — | — | US | disclosed |
| US-7381737-B2 | Crystalline forms and process for preparing spiro-hydantoin compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1836209-A1 | CRYSTALLINE FORMS OF6-[(5S,9R)-9-(4-CYANOPHENYL)-3-(3,5-DICHLOROPHENYL)-1-METHYL-2,4-DIOXO-1,3,7-TRIAZASPIRO[4.4]NON-7-YL]NICOTINIC ACID AS INHIBITORS OF CD18 INTEGRINS, ICAMS AND/OR THE LFA-1:ICAM INTERACTION FOR THE TREATMENT OF INFLAMMATIONS AND IMMUNE DISEASES | Bristol-Myers Squibb Company (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1828193-A1 | PYRIDIL-SUBSTITUTED SPIRO-HYDANTOIN COMPOUNDS AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1802628-A1 | CRYSTALLINE FORMS AND PROCESS FOR PREPARING SPIRO-HYDANTOIN COMPOUNDS | Bristol-Myers Squibb Company (US) | 2007-07-04 | — | — | EP | disclosed |
| US-7186727-B2 | Pyridyl-substituted spiro-hydantoin compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060148836-A1 | Pyridyl-substituted spiro-hydantoin compounds and use thereof | CEREP S.A. (FR) | 2006-07-06 | — | — | US | disclosed |
| US-20060142319-A1 | Pyridyl-substituted spiro-hydantoin crystalline forms and process | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-29 | — | — | US | disclosed |
| WO-2006065908-A1 | CRYSTALLINE FORMS OF6- [(5S, 9R) -9- (4-CYANOPHENYL) -3-(3, 5-DICHLOROPHENYL) -1-METHYL-2, 4-DIOXO-1, 3, 7-TRIAZASPIRO [4.4] NON-7-YL] NICOTINIC | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065919-A1 | PYRIDIL-SUBSTITUTED SPIRO-HYDANTOIN COMPOUNDS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006039639-A1 | CRYSTALLINE FORMS AND PROCESS FOR PREPARING SPIRO-HYDANTOIN COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074099-A1 | Crystalline forms and process for preparing spiro-hydantoin compounds | BRISTOL-MYERS SQUIBB COMPANY | 2006-04-06 | — | — | US | disclosed |